Company: BDRX
Filing Date: 2025-11-17
Form Type: POS AM
Source: 0001214659-25-016809
Chunk: 15

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: POS AM
Chunk 15
---
 of a substantial amount of our Ordinary Shares (represented by Depositary Shares), including resale of the Ordinary Shares (represented by Depositary Shares) issuable upon the exercise of the warrants held by the selling shareholders in the public market could adversely affect the prevailing market price of our Ordinary Shares and/or Depositary Shares.

We are registering for resale 109,800,000
Ordinary Shares represented by 1,098 Depositary Shares issuable upon the exercise of warrants held by the selling shareholders. Sales
of substantial amounts of our Ordinary Shares and/or Depositary Shares in the public market, or the perception that such sales may occur,
could adversely affect the market price of our Ordinary Shares and/or Depositary Shares. We cannot predict if and when selling shareholders
may sell such shares in the public markets. Furthermore, in the future, we may issue additional Ordinary Shares (including Ordinary Shares
represented by Depositary Shares). Any such issuance could result in substantial dilution to our existing shareholders and could cause
our share price to decline.

| 9 |

<div align='center'>USE OF PROCEEDS</div>

We will not receive any proceeds from
the sale of the Ordinary Shares represented by Depositary Shares by the selling shareholders. All net proceeds from the sale of the Ordinary
Shares represented by Depositary Shares and the Series D Warrants covered by this prospectus will go to the selling shareholders. We
expect that the selling shareholders will sell their Ordinary Shares represented by Depositary Shares as described under “Plan
of Distribution.”

We may receive proceeds from the exercise
of the Series D Warrants and issuance of the Depositary Shares underlying the warrants. If all of the Series D Warrants mentioned above
were exercised for cash in full, the proceeds would be approximately $4.4 million. We currently intend to use the net proceeds of such
warrant exercise, if any, to fund our clinical development programs and for working capital and general corporate purpose. Pending such
uses, we intend to invest the net proceeds in short-term, interest-bearing investments.

We can make no assurances that any
of the Series D Warrants will be exercised, or if exercised, the quantity which will be exercised or in the period in which they will
be exercised.

| 10 |

<div align='center'>DIVIDEND POLICY</div>

Since inception,
we have never declared or paid any cash dividends on our Ordinary Shares and do not anticipate paying any cash dividends on our Ordinary
Shares or the Depositary Shares in the foreseeable future. We